761 related articles for article (PubMed ID: 24026528)
21. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Sun Y; Li L; Zhou TY; Lu W
Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
[TBL] [Abstract][Full Text] [Related]
22. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
23. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
25. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
26. Febuxostat for treatment of chronic gout.
Gray CL; Walters-Smith NE
Am J Health Syst Pharm; 2011 Mar; 68(5):389-98. PubMed ID: 21330679
[TBL] [Abstract][Full Text] [Related]
27. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Uh M; Reid G
J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
[TBL] [Abstract][Full Text] [Related]
28. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
[TBL] [Abstract][Full Text] [Related]
29. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan S
J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
[TBL] [Abstract][Full Text] [Related]
31. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Borghi C; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
[TBL] [Abstract][Full Text] [Related]
32. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
33. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
34. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
35. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
Wells AF; MacDonald PA; Chefo S; Jackson RL
BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
[TBL] [Abstract][Full Text] [Related]
37. Febuxostat: a new treatment for hyperuricaemia in gout.
Edwards NL
Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
[TBL] [Abstract][Full Text] [Related]
38. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat versus allopurinol for gout.
Gelber AC
N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
[No Abstract] [Full Text] [Related]
40. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Hilmi BA; Asmahan MI; Rosman A
Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]